I am a
Home I AM A Search Login

Accepted

Share this

Neocortical in vivo focal and spreading potassium responses and the influence of astrocytic gap junctional coupling.

Raised extracellular potassium ion (K) concentration is associated with several disorders including migraine, stroke, neurotrauma and epilepsy. K spatial buffering is a well-known mechanism for extracellular K regulation/distribution. Astrocytic gap junction-mediated buffering is a controversial candidate for K spatial buffering. To further investigate the existence of a K spatial buffering and to assess the involvement of astrocytic gap junctional coupling in K redistribution, we hypothesized that neocortical K and concomitant spreading depolarization (SD)-like responses are controlled by powerful local K buffering mechanisms and that K buffering/redistribution occurs partially through gap junctional coupling. Herein, we show, in vivo, that a threshold amount of focally applied KCl is required to trigger local and/or distal K responses, accompanied by a SD-like response. This observation indicates the presence of powerful local K buffering which mediates a rapid return of extracellular K to the baseline. Application of gap junctional blockers, carbenoxolone and Gap27, partially modulated the amplitude and shape of the K response and noticeably decreased the velocity of the spreading K and SD-like responses. Opening of gap junctions by trimethylamine, slightly decreased the amplitude of the K response and markedly increased the velocity of redistribution of K and SD-like events. We conclude that spreading K responses reflect powerful local K buffering mechanisms which are partially modulated by gap junctional communication. Gap junctional coupling mainly affected the velocity of the K and SD-like responses.

Learn More >

Efficacy of motivational-interviewing and guided opioid tapering support for patients undergoing orthopedic surgery (MI-Opioid Taper): A prospective, assessor-blind, randomized controlled pilot trial.

Postoperative opioid use can lead to chronic use and misuse. Few studies have examined effective approaches to taper postoperative opioid use while maintaining adequate analgesia.

Learn More >

Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study.

To study the characteristics of headache attributed to COVID-19 infection and predictors of its severity.

Learn More >

Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study.

The literature suggests patient characteristics and higher opioid doses and long-term duration are associated with problematic opioid behaviours but no one study has examined the role of all these factors simultaneously in a long-term prospective cohort study.

Learn More >

Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients.

Headache is a common symptom of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this study, we aimed to characterize the phenotype of headache attributed to SARS-CoV-2 infection and to test the International Classification of Headache Disorders (ICHD-3) phenotypic criteria for migraine and tension-type headache.

Learn More >

Predicting the Future of Migraine Attack Prediction.

Learn More >

Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution.

To define headache characteristics and evolution in relation to COVID-19 and its inflammatory response.

Learn More >

OnabotulinumtoxinA.

Learn More >

Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia.

To assess the frequency and characteristics of headache in patients with COVID-19 and whether there is an association between headache and anosmia and ageusia.

Learn More >

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.

This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient-reported outcomes of health-related quality of life (HRQoL) and disability categories.

Learn More >

Search